Inpharma Weekly

, Volume 952, Issue 1, pp 3–3 | Cite as

New antitumour drug beats resistance

  • Ian Mundell
Newsletter Article


An anticancer drug that has ‘languished’ in an academic laboratory for 10 years has been taken into clinical trials by the UK Cancer Research Campaign (CRC), in collaboration with biotech company Xenova (Slough, UK). The drug promises good antitumour efficacy but, more importantly, it appears to be unique in its ability to transcend 2 forms of drug resistance.


Financial Analyst Biotech Company Academic Laboratory P388 Leukaemia Commercial Partner 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1994

Authors and Affiliations

  • Ian Mundell

There are no affiliations available

Personalised recommendations